A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study

BACKGROUND: Osimertinib is one of the standard first-line treatments for advanced non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations, because it achieves significantly longer progression-free survival (PFS) than conventional first-line treatments (hazard ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Chihara, Yusuke, Takeda, Takayuki, Goto, Yasuhiro, Nakamura, Yoichi, Tsuchiya-Kawano, Yuko, Nakao, Akira, Onoi, Keisuke, Hibino, Makoto, Fukuda, Minoru, Honda, Ryoichi, Yamada, Takahiro, Taniguchi, Ryusuke, Sakamoto, Sinjiro, Date, Koji, Nagashima, Seiji, Tanzawa, Shigeru, Minato, Koichi, Nakatani, Koichi, Izumi, Miiru, Shimose, Takayuki, Kishimoto, Junji, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632307/
https://www.ncbi.nlm.nih.gov/pubmed/36181763
http://dx.doi.org/10.1093/oncolo/oyac193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632307/
https://www.ncbi.nlm.nih.gov/pubmed/36181763
http://dx.doi.org/10.1093/oncolo/oyac193

Ejemplares similares